 Rasika Mathias
Concepts (724)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 78 | 2023 | 1197 | 4.610 |
Why?
| | Polymorphism, Single Nucleotide | 92 | 2023 | 1892 | 4.590 |
Why?
| | Genetic Predisposition to Disease | 63 | 2022 | 2099 | 3.650 |
Why?
| | Peanut Hypersensitivity | 6 | 2023 | 197 | 2.860 |
Why?
| | Asthma | 46 | 2023 | 2032 | 2.610 |
Why?
| | Dermatitis, Atopic | 9 | 2023 | 307 | 2.420 |
Why?
| | Fatty Acid Desaturases | 12 | 2021 | 29 | 2.090 |
Why?
| | Genetic Variation | 29 | 2022 | 876 | 2.010 |
Why?
| | Precision Medicine | 18 | 2024 | 338 | 2.000 |
Why?
| | Immunoglobulin E | 18 | 2021 | 316 | 1.960 |
Why?
| | Whole Genome Sequencing | 21 | 2023 | 94 | 1.960 |
Why?
| | Food Hypersensitivity | 4 | 2023 | 253 | 1.930 |
Why?
| | Induced Pluripotent Stem Cells | 4 | 2021 | 182 | 1.860 |
Why?
| | Platelet Aggregation | 12 | 2021 | 94 | 1.860 |
Why?
| | Arachis | 5 | 2023 | 146 | 1.830 |
Why?
| | Genome, Human | 16 | 2023 | 351 | 1.830 |
Why?
| | Genotype | 41 | 2022 | 1774 | 1.730 |
Why?
| | Exome | 14 | 2022 | 200 | 1.720 |
Why?
| | Blood Platelets | 12 | 2022 | 351 | 1.620 |
Why?
| | Alleles | 22 | 2023 | 791 | 1.530 |
Why?
| | Kaposi Varicelliform Eruption | 4 | 2021 | 22 | 1.490 |
Why?
| | Megakaryocytes | 3 | 2021 | 30 | 1.350 |
Why?
| | Genetic Loci | 18 | 2021 | 263 | 1.260 |
Why?
| | Genomics | 13 | 2024 | 639 | 1.260 |
Why?
| | Fatty Acids, Omega-6 | 5 | 2017 | 45 | 1.230 |
Why?
| | Quantitative Trait Loci | 16 | 2022 | 307 | 1.180 |
Why?
| | Humans | 216 | 2024 | 114756 | 1.160 |
Why?
| | Phenotype | 44 | 2023 | 2812 | 1.140 |
Why?
| | Multigene Family | 9 | 2021 | 193 | 1.110 |
Why?
| | Genetics, Population | 14 | 2021 | 188 | 0.990 |
Why?
| | Coronary Artery Disease | 10 | 2023 | 607 | 0.980 |
Why?
| | Gene Frequency | 22 | 2022 | 481 | 0.970 |
Why?
| | Linoleic Acid | 6 | 2023 | 38 | 0.950 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 12 | 2022 | 93 | 0.940 |
Why?
| | Transcriptome | 3 | 2022 | 727 | 0.920 |
Why?
| | Hypersensitivity, Immediate | 2 | 2023 | 46 | 0.880 |
Why?
| | Allergens | 5 | 2023 | 413 | 0.880 |
Why?
| | Receptors, Cell Surface | 7 | 2022 | 354 | 0.870 |
Why?
| | Genetic Linkage | 14 | 2022 | 297 | 0.850 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2022 | 14 | 0.830 |
Why?
| | Chromosome Mapping | 16 | 2021 | 489 | 0.810 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 11 | 2021 | 916 | 0.790 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2019 | 440 | 0.780 |
Why?
| | 2S Albumins, Plant | 1 | 2022 | 25 | 0.780 |
Why?
| | Linkage Disequilibrium | 19 | 2022 | 245 | 0.780 |
Why?
| | Antigens, Plant | 1 | 2022 | 47 | 0.770 |
Why?
| | Nucleotide Transport Proteins | 1 | 2021 | 1 | 0.760 |
Why?
| | Models, Genetic | 12 | 2021 | 565 | 0.760 |
Why?
| | Immunoglobulin G | 2 | 2022 | 774 | 0.750 |
Why?
| | Lipids | 8 | 2023 | 582 | 0.730 |
Why?
| | Antibody Formation | 1 | 2022 | 267 | 0.710 |
Why?
| | Herpesvirus 1, Human | 1 | 2021 | 76 | 0.700 |
Why?
| | Platelet Function Tests | 3 | 2021 | 24 | 0.700 |
Why?
| | Male | 97 | 2022 | 55579 | 0.700 |
Why?
| | Female | 98 | 2023 | 59507 | 0.660 |
Why?
| | Lung | 9 | 2022 | 3546 | 0.640 |
Why?
| | Middle Aged | 61 | 2023 | 26757 | 0.640 |
Why?
| | Genetic Association Studies | 12 | 2021 | 344 | 0.630 |
Why?
| | Open Reading Frames | 3 | 2021 | 116 | 0.630 |
Why?
| | Alzheimer Disease | 1 | 2023 | 443 | 0.610 |
Why?
| | Adult | 62 | 2023 | 30548 | 0.600 |
Why?
| | Chromosomes, Human, Pair 11 | 5 | 2014 | 58 | 0.550 |
Why?
| | Human Migration | 1 | 2016 | 19 | 0.540 |
Why?
| | Gene-Environment Interaction | 3 | 2014 | 184 | 0.540 |
Why?
| | Platelet Activation | 4 | 2018 | 68 | 0.530 |
Why?
| | Diabetes Mellitus, Type 2 | 10 | 2022 | 2097 | 0.530 |
Why?
| | Pulmonary Emphysema | 3 | 2014 | 268 | 0.530 |
Why?
| | Gene Flow | 1 | 2016 | 77 | 0.520 |
Why?
| | Evolution, Molecular | 3 | 2019 | 437 | 0.500 |
Why?
| | RNA | 1 | 2021 | 810 | 0.490 |
Why?
| | Geography | 2 | 2016 | 180 | 0.470 |
Why?
| | Diet | 4 | 2023 | 1080 | 0.470 |
Why?
| | Multifactorial Inheritance | 3 | 2022 | 125 | 0.460 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 7 | 0.450 |
Why?
| | Polymorphism, Genetic | 11 | 2017 | 612 | 0.450 |
Why?
| | Fatty Acids, Unsaturated | 4 | 2020 | 84 | 0.440 |
Why?
| | Bronchial Hyperreactivity | 1 | 2014 | 95 | 0.440 |
Why?
| | Pedigree | 7 | 2020 | 464 | 0.420 |
Why?
| | Interferon-gamma | 3 | 2015 | 722 | 0.420 |
Why?
| | Quantitative Trait, Heritable | 6 | 2021 | 117 | 0.420 |
Why?
| | Child | 29 | 2023 | 18352 | 0.410 |
Why?
| | Computational Biology | 4 | 2024 | 530 | 0.400 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2021 | 122 | 0.390 |
Why?
| | Immunity, Cellular | 1 | 2013 | 248 | 0.390 |
Why?
| | Fibrinogen | 6 | 2021 | 154 | 0.390 |
Why?
| | Airway Obstruction | 1 | 2014 | 168 | 0.390 |
Why?
| | Risk Factors | 19 | 2023 | 8627 | 0.380 |
Why?
| | Leukocytes | 4 | 2023 | 277 | 0.380 |
Why?
| | Haplotypes | 12 | 2021 | 453 | 0.370 |
Why?
| | United States | 28 | 2022 | 12176 | 0.370 |
Why?
| | Likelihood Functions | 5 | 2012 | 126 | 0.370 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2011 | 53 | 0.370 |
Why?
| | Dyslipidemias | 3 | 2016 | 154 | 0.370 |
Why?
| | Software | 4 | 2021 | 536 | 0.370 |
Why?
| | Aging | 4 | 2023 | 1620 | 0.370 |
Why?
| | Adolescent | 27 | 2023 | 17808 | 0.360 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 904 | 0.360 |
Why?
| | Cohort Studies | 15 | 2021 | 4901 | 0.360 |
Why?
| | DNA Methylation | 4 | 2023 | 496 | 0.360 |
Why?
| | Case-Control Studies | 18 | 2021 | 3005 | 0.350 |
Why?
| | DNA, Mitochondrial | 2 | 2023 | 182 | 0.350 |
Why?
| | RNA, Long Noncoding | 2 | 2023 | 154 | 0.350 |
Why?
| | Genome | 4 | 2022 | 272 | 0.350 |
Why?
| | Mutation | 7 | 2023 | 3350 | 0.340 |
Why?
| | Organ Specificity | 2 | 2021 | 268 | 0.320 |
Why?
| | Smoking | 6 | 2018 | 1384 | 0.320 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 483 | 0.320 |
Why?
| | Pharmacogenetics | 2 | 2020 | 149 | 0.310 |
Why?
| | Mosaicism | 2 | 2023 | 61 | 0.310 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 689 | 0.310 |
Why?
| | Mendelian Randomization Analysis | 2 | 2019 | 43 | 0.310 |
Why?
| | Genetic Pleiotropy | 3 | 2019 | 29 | 0.310 |
Why?
| | Dietary Fats | 1 | 2010 | 287 | 0.310 |
Why?
| | Aged | 28 | 2023 | 19094 | 0.300 |
Why?
| | HLA-DQ beta-Chains | 2 | 2021 | 58 | 0.290 |
Why?
| | Fasting | 2 | 2022 | 242 | 0.290 |
Why?
| | Arachidonic Acid | 6 | 2015 | 116 | 0.290 |
Why?
| | Computer Simulation | 7 | 2020 | 878 | 0.280 |
Why?
| | Aspirin | 4 | 2018 | 324 | 0.280 |
Why?
| | Cardiovascular Diseases | 7 | 2020 | 1727 | 0.280 |
Why?
| | Epigenesis, Genetic | 5 | 2023 | 521 | 0.280 |
Why?
| | Body Height | 4 | 2015 | 180 | 0.280 |
Why?
| | Loss of Function Mutation | 3 | 2021 | 36 | 0.280 |
Why?
| | Restless Legs Syndrome | 1 | 2006 | 19 | 0.270 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2006 | 15 | 0.270 |
Why?
| | Computer Graphics | 1 | 2006 | 41 | 0.260 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2006 | 65 | 0.260 |
Why?
| | Young Adult | 13 | 2022 | 10463 | 0.260 |
Why?
| | Schistosoma japonicum | 2 | 2017 | 31 | 0.260 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 95 | 0.260 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 54 | 0.260 |
Why?
| | von Willebrand Factor | 4 | 2015 | 56 | 0.260 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 743 | 0.250 |
Why?
| | Membrane Proteins | 7 | 2017 | 1022 | 0.250 |
Why?
| | Serine | 1 | 2006 | 126 | 0.250 |
Why?
| | Models, Statistical | 7 | 2021 | 604 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2269 | 0.250 |
Why?
| | Helminthiasis | 2 | 2017 | 10 | 0.250 |
Why?
| | Hematopoiesis | 2 | 2023 | 172 | 0.250 |
Why?
| | Germ-Line Mutation | 2 | 2023 | 130 | 0.240 |
Why?
| | Cholesterol, HDL | 4 | 2016 | 184 | 0.240 |
Why?
| | Consanguinity | 2 | 2005 | 47 | 0.240 |
Why?
| | Blood Pressure | 6 | 2022 | 1530 | 0.240 |
Why?
| | Interleukin-13 | 3 | 2023 | 122 | 0.230 |
Why?
| | Liver Cirrhosis | 2 | 2017 | 228 | 0.230 |
Why?
| | Chromosomes, Human, Pair 16 | 3 | 2021 | 30 | 0.230 |
Why?
| | Chemokines, CC | 2 | 2014 | 28 | 0.230 |
Why?
| | Erythrocytes | 2 | 2021 | 591 | 0.230 |
Why?
| | Forced Expiratory Volume | 4 | 2019 | 476 | 0.230 |
Why?
| | Liver | 5 | 2021 | 1631 | 0.230 |
Why?
| | Menopause, Premature | 1 | 2023 | 8 | 0.220 |
Why?
| | Health Status Disparities | 2 | 2017 | 201 | 0.220 |
Why?
| | Hypersensitivity | 3 | 2023 | 254 | 0.220 |
Why?
| | Population Groups | 3 | 2019 | 57 | 0.220 |
Why?
| | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 2 | 2022 | 2 | 0.220 |
Why?
| | Barbados | 8 | 2013 | 8 | 0.220 |
Why?
| | Biomarkers | 5 | 2021 | 3416 | 0.220 |
Why?
| | Metabolic Syndrome | 3 | 2011 | 323 | 0.220 |
Why?
| | Respiration | 2 | 2014 | 179 | 0.210 |
Why?
| | Frameshift Mutation | 1 | 2022 | 27 | 0.210 |
Why?
| | Blood Cells | 1 | 2022 | 38 | 0.210 |
Why?
| | Hematopoietic Stem Cells | 2 | 2023 | 345 | 0.210 |
Why?
| | Promoter Regions, Genetic | 6 | 2023 | 1133 | 0.210 |
Why?
| | Chromosomes, Human, X | 2 | 2021 | 60 | 0.210 |
Why?
| | Interleukin-4 | 2 | 2023 | 208 | 0.210 |
Why?
| | Telomere Shortening | 1 | 2022 | 17 | 0.200 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 184 | 0.200 |
Why?
| | Gastritis | 1 | 2023 | 84 | 0.200 |
Why?
| | Acute Coronary Syndrome | 2 | 2016 | 254 | 0.200 |
Why?
| | Genetic Heterogeneity | 3 | 2016 | 49 | 0.200 |
Why?
| | Enteritis | 1 | 2023 | 82 | 0.200 |
Why?
| | Nerve Tissue Proteins | 5 | 2022 | 529 | 0.200 |
Why?
| | Gene Expression Regulation | 7 | 2021 | 2321 | 0.200 |
Why?
| | Eczema | 1 | 2023 | 81 | 0.200 |
Why?
| | Coronary Disease | 2 | 2019 | 347 | 0.200 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 36 | 0.190 |
Why?
| | Healthcare Disparities | 2 | 2017 | 479 | 0.190 |
Why?
| | Dinoprostone | 1 | 2022 | 184 | 0.190 |
Why?
| | Desensitization, Immunologic | 1 | 2023 | 117 | 0.190 |
Why?
| | Americas | 1 | 2021 | 19 | 0.190 |
Why?
| | Cytokines | 4 | 2023 | 1843 | 0.190 |
Why?
| | Spain | 1 | 2021 | 32 | 0.190 |
Why?
| | DNA Copy Number Variations | 2 | 2020 | 158 | 0.190 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2014 | 72 | 0.190 |
Why?
| | Peru | 1 | 2021 | 54 | 0.190 |
Why?
| | Gene Ontology | 1 | 2021 | 45 | 0.190 |
Why?
| | Lipid Metabolism | 2 | 2021 | 446 | 0.190 |
Why?
| | Odds Ratio | 7 | 2019 | 954 | 0.180 |
Why?
| | Frailty | 1 | 2023 | 114 | 0.180 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2021 | 83 | 0.180 |
Why?
| | Glutathione Transferase | 1 | 2021 | 94 | 0.180 |
Why?
| | Pulmonary Medicine | 2 | 2019 | 87 | 0.180 |
Why?
| | Receptors, Nicotinic | 2 | 2013 | 274 | 0.180 |
Why?
| | Immunologic Factors | 1 | 2022 | 220 | 0.180 |
Why?
| | Risk | 7 | 2019 | 815 | 0.180 |
Why?
| | Energy Intake | 1 | 2023 | 427 | 0.180 |
Why?
| | gamma-Linolenic Acid | 1 | 2020 | 2 | 0.180 |
Why?
| | Chromosomes, Human, Pair 19 | 3 | 2012 | 22 | 0.180 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 400 | 0.180 |
Why?
| | Plant Oils | 1 | 2020 | 26 | 0.180 |
Why?
| | Soybean Oil | 1 | 2020 | 12 | 0.180 |
Why?
| | HLA-DQ Antigens | 1 | 2021 | 176 | 0.180 |
Why?
| | Amish | 1 | 2020 | 7 | 0.170 |
Why?
| | Genomic Instability | 1 | 2020 | 38 | 0.170 |
Why?
| | beta-Globins | 1 | 2019 | 10 | 0.170 |
Why?
| | Cholesterol, LDL | 5 | 2022 | 307 | 0.170 |
Why?
| | Diabetic Nephropathies | 1 | 2023 | 234 | 0.170 |
Why?
| | Base Sequence | 4 | 2021 | 2118 | 0.170 |
Why?
| | Brain | 2 | 2023 | 2374 | 0.170 |
Why?
| | Occipital Lobe | 1 | 2019 | 23 | 0.170 |
Why?
| | Child, Preschool | 16 | 2021 | 9079 | 0.170 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 935 | 0.170 |
Why?
| | HLA-DRB1 Chains | 1 | 2020 | 98 | 0.170 |
Why?
| | Mutation, Missense | 2 | 2023 | 295 | 0.170 |
Why?
| | Homozygote | 3 | 2016 | 187 | 0.170 |
Why?
| | Sex Characteristics | 3 | 2014 | 640 | 0.170 |
Why?
| | Blood Glucose | 4 | 2021 | 1821 | 0.170 |
Why?
| | Parietal Lobe | 1 | 2019 | 41 | 0.160 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 3 | 2020 | 6 | 0.160 |
Why?
| | Eicosanoids | 2 | 2022 | 54 | 0.160 |
Why?
| | Family | 4 | 2012 | 591 | 0.160 |
Why?
| | Brazil | 6 | 2017 | 90 | 0.160 |
Why?
| | Th2 Cells | 4 | 2023 | 154 | 0.160 |
Why?
| | Chromosomes, Human, Pair 12 | 4 | 2019 | 20 | 0.160 |
Why?
| | Photometry | 1 | 2019 | 2 | 0.160 |
Why?
| | India | 3 | 2009 | 134 | 0.160 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 225 | 0.160 |
Why?
| | Chromatography, Gas | 1 | 2019 | 27 | 0.160 |
Why?
| | Flame Retardants | 1 | 2019 | 8 | 0.160 |
Why?
| | Temporal Lobe | 1 | 2019 | 79 | 0.160 |
Why?
| | Genes, Mitochondrial | 1 | 2018 | 12 | 0.160 |
Why?
| | Receptors, Immunologic | 3 | 2022 | 201 | 0.160 |
Why?
| | Plasticizers | 1 | 2019 | 12 | 0.160 |
Why?
| | Sleep Medicine Specialty | 1 | 2019 | 9 | 0.160 |
Why?
| | Telomere | 4 | 2023 | 202 | 0.160 |
Why?
| | Metabolism | 1 | 2018 | 35 | 0.160 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 296 | 0.160 |
Why?
| | Immunotherapy | 1 | 2022 | 475 | 0.160 |
Why?
| | Databases, Genetic | 4 | 2021 | 206 | 0.160 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 10 | 0.160 |
Why?
| | Indians, North American | 2 | 2021 | 570 | 0.160 |
Why?
| | Smad2 Protein | 1 | 2018 | 33 | 0.160 |
Why?
| | Exons | 3 | 2016 | 303 | 0.160 |
Why?
| | DNA-Binding Proteins | 3 | 2020 | 1314 | 0.150 |
Why?
| | Hominidae | 1 | 2019 | 79 | 0.150 |
Why?
| | Frontal Lobe | 1 | 2019 | 140 | 0.150 |
Why?
| | Computer Communication Networks | 1 | 2018 | 32 | 0.150 |
Why?
| | Comorbidity | 1 | 2023 | 1449 | 0.150 |
Why?
| | Organophosphates | 1 | 2019 | 91 | 0.150 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2010 | 82 | 0.150 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 347 | 0.150 |
Why?
| | Aged, 80 and over | 9 | 2020 | 6350 | 0.150 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2017 | 29 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 486 | 0.150 |
Why?
| | Africa | 2 | 2020 | 95 | 0.150 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 604 | 0.150 |
Why?
| | Noncommunicable Diseases | 1 | 2017 | 14 | 0.150 |
Why?
| | Quality Control | 4 | 2021 | 144 | 0.150 |
Why?
| | Information Storage and Retrieval | 1 | 2018 | 107 | 0.140 |
Why?
| | Hyaluronoglucosaminidase | 1 | 2017 | 8 | 0.140 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2017 | 81 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 176 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2020 | 413 | 0.140 |
Why?
| | Molecular Epidemiology | 3 | 2013 | 62 | 0.140 |
Why?
| | Endemic Diseases | 1 | 2017 | 23 | 0.140 |
Why?
| | Animals | 18 | 2023 | 31761 | 0.140 |
Why?
| | Schistosoma mansoni | 1 | 2017 | 33 | 0.140 |
Why?
| | Sequence Analysis, DNA | 6 | 2018 | 728 | 0.140 |
Why?
| | Lung Diseases, Interstitial | 1 | 2022 | 507 | 0.140 |
Why?
| | White Matter | 1 | 2018 | 104 | 0.140 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 22 | 0.140 |
Why?
| | Inflammation | 5 | 2023 | 2481 | 0.140 |
Why?
| | Scavenger Receptors, Class B | 1 | 2016 | 8 | 0.140 |
Why?
| | Enhancer Elements, Genetic | 1 | 2017 | 152 | 0.140 |
Why?
| | Myocardial Infarction | 2 | 2020 | 927 | 0.140 |
Why?
| | DNA, Intergenic | 1 | 2016 | 24 | 0.140 |
Why?
| | Cyclooxygenase 1 | 2 | 2014 | 20 | 0.140 |
Why?
| | Schistosomiasis | 1 | 2017 | 37 | 0.140 |
Why?
| | Carotid Artery Diseases | 1 | 2016 | 57 | 0.140 |
Why?
| | Cell Differentiation | 2 | 2021 | 1699 | 0.140 |
Why?
| | Erythropoiesis | 1 | 2016 | 34 | 0.140 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 220 | 0.130 |
Why?
| | Kidney Transplantation | 2 | 2012 | 541 | 0.130 |
Why?
| | Immune System Diseases | 1 | 2016 | 32 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 498 | 0.130 |
Why?
| | Lipoprotein(a) | 1 | 2016 | 51 | 0.130 |
Why?
| | Sexism | 1 | 2016 | 44 | 0.130 |
Why?
| | Thrombosis | 4 | 2021 | 297 | 0.130 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 153 | 0.130 |
Why?
| | Cell Adhesion Molecules | 1 | 2017 | 168 | 0.130 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 493 | 0.130 |
Why?
| | United Kingdom | 3 | 2021 | 226 | 0.130 |
Why?
| | Anthropometry | 2 | 2022 | 183 | 0.130 |
Why?
| | Metabolomics | 1 | 2020 | 527 | 0.130 |
Why?
| | CpG Islands | 3 | 2023 | 117 | 0.130 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 139 | 0.130 |
Why?
| | Genes, Modifier | 1 | 2015 | 1 | 0.130 |
Why?
| | Caveolin 2 | 1 | 2015 | 3 | 0.130 |
Why?
| | Molecular Sequence Annotation | 3 | 2021 | 81 | 0.130 |
Why?
| | Collagen | 2 | 2015 | 415 | 0.130 |
Why?
| | Factor VII | 1 | 2015 | 26 | 0.130 |
Why?
| | Receptors, Interferon | 1 | 2015 | 47 | 0.130 |
Why?
| | Hypertension | 2 | 2022 | 1059 | 0.130 |
Why?
| | Minority Groups | 1 | 2017 | 227 | 0.120 |
Why?
| | Factor VIII | 1 | 2015 | 54 | 0.120 |
Why?
| | Severity of Illness Index | 4 | 2019 | 2539 | 0.120 |
Why?
| | Schistosomiasis japonica | 1 | 2015 | 32 | 0.120 |
Why?
| | Menopause | 2 | 2023 | 271 | 0.120 |
Why?
| | Scleroderma, Systemic | 1 | 2016 | 96 | 0.120 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 153 | 0.120 |
Why?
| | Body Mass Index | 5 | 2022 | 1958 | 0.120 |
Why?
| | Interleukin-10 | 2 | 2017 | 296 | 0.120 |
Why?
| | Mutation Rate | 1 | 2015 | 26 | 0.120 |
Why?
| | Mutant Chimeric Proteins | 1 | 2014 | 3 | 0.120 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2014 | 4 | 0.120 |
Why?
| | Obesity | 2 | 2022 | 2513 | 0.120 |
Why?
| | Critical Care | 1 | 2019 | 473 | 0.120 |
Why?
| | HMGA2 Protein | 1 | 2014 | 8 | 0.120 |
Why?
| | HLA-B27 Antigen | 1 | 2014 | 11 | 0.120 |
Why?
| | Chromosome Disorders | 1 | 2014 | 35 | 0.120 |
Why?
| | Cystic Fibrosis | 2 | 2015 | 955 | 0.120 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2014 | 24 | 0.120 |
Why?
| | Longitudinal Studies | 5 | 2021 | 2386 | 0.120 |
Why?
| | Rhinitis, Allergic | 1 | 2014 | 35 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2017 | 460 | 0.110 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 298 | 0.110 |
Why?
| | Family Health | 4 | 2011 | 194 | 0.110 |
Why?
| | Algorithms | 5 | 2013 | 1468 | 0.110 |
Why?
| | Stroke | 1 | 2022 | 1019 | 0.110 |
Why?
| | Parents | 3 | 2007 | 1190 | 0.110 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 3 | 0.110 |
Why?
| | Vital Capacity | 1 | 2014 | 256 | 0.110 |
Why?
| | beta-Defensins | 1 | 2013 | 18 | 0.110 |
Why?
| | Tobacco Use Disorder | 2 | 2013 | 234 | 0.110 |
Why?
| | HEK293 Cells | 3 | 2021 | 593 | 0.110 |
Why?
| | Mitochondria | 1 | 2018 | 751 | 0.110 |
Why?
| | Cells, Cultured | 1 | 2021 | 3890 | 0.110 |
Why?
| | Nuclear Proteins | 1 | 2017 | 592 | 0.110 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.110 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 74 | 0.110 |
Why?
| | Virginia | 2 | 2005 | 51 | 0.110 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2011 | 67 | 0.110 |
Why?
| | Microbiota | 1 | 2020 | 648 | 0.110 |
Why?
| | Phylogeny | 1 | 2016 | 794 | 0.110 |
Why?
| | Genetic Markers | 5 | 2016 | 321 | 0.110 |
Why?
| | Principal Component Analysis | 2 | 2010 | 176 | 0.110 |
Why?
| | Fatty Acids | 1 | 2015 | 382 | 0.110 |
Why?
| | Atherosclerosis | 1 | 2016 | 342 | 0.110 |
Why?
| | Ankyrins | 1 | 2012 | 7 | 0.100 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2012 | 9 | 0.100 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 228 | 0.100 |
Why?
| | Skin Tests | 4 | 2017 | 122 | 0.100 |
Why?
| | Telomerase | 1 | 2014 | 206 | 0.100 |
Why?
| | Duffy Blood-Group System | 2 | 2011 | 5 | 0.100 |
Why?
| | Kallikreins | 1 | 2012 | 30 | 0.100 |
Why?
| | Insulin | 4 | 2022 | 2079 | 0.100 |
Why?
| | Triglycerides | 3 | 2015 | 470 | 0.100 |
Why?
| | Infant | 9 | 2021 | 7935 | 0.100 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2012 | 44 | 0.100 |
Why?
| | Leukocyte Count | 2 | 2011 | 292 | 0.100 |
Why?
| | Respiratory Sounds | 1 | 2012 | 111 | 0.100 |
Why?
| | Disease Progression | 5 | 2019 | 2387 | 0.100 |
Why?
| | Reproducibility of Results | 6 | 2021 | 2763 | 0.100 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 153 | 0.100 |
Why?
| | Chromosome Aberrations | 1 | 2012 | 138 | 0.100 |
Why?
| | Steroids | 1 | 2012 | 145 | 0.100 |
Why?
| | Heterozygote | 3 | 2021 | 251 | 0.100 |
Why?
| | Mice | 10 | 2023 | 14916 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 14 | 0.090 |
Why?
| | Microtubule-Associated Proteins | 1 | 2012 | 174 | 0.090 |
Why?
| | Interviews as Topic | 2 | 2006 | 582 | 0.090 |
Why?
| | Aquaporin 5 | 1 | 2010 | 2 | 0.090 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 43 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2017 | 763 | 0.090 |
Why?
| | Chromosomes | 1 | 2011 | 87 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3039 | 0.090 |
Why?
| | Heredity | 2 | 2021 | 12 | 0.090 |
Why?
| | Cockroaches | 1 | 2010 | 21 | 0.090 |
Why?
| | Incidence | 4 | 2019 | 2312 | 0.090 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2010 | 24 | 0.090 |
Why?
| | Recombination, Genetic | 1 | 2011 | 176 | 0.090 |
Why?
| | Death Domain Receptor Signaling Adaptor Proteins | 1 | 2009 | 2 | 0.090 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2010 | 33 | 0.090 |
Why?
| | Lectins | 1 | 2010 | 43 | 0.090 |
Why?
| | Myocardial Ischemia | 1 | 2011 | 234 | 0.090 |
Why?
| | Receptors, Kainic Acid | 1 | 2009 | 10 | 0.080 |
Why?
| | Cross-Sectional Studies | 4 | 2023 | 4409 | 0.080 |
Why?
| | Tryptophan | 1 | 2010 | 135 | 0.080 |
Why?
| | Nuclear Family | 2 | 2007 | 49 | 0.080 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2009 | 55 | 0.080 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2009 | 58 | 0.080 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2009 | 6 | 0.080 |
Why?
| | Isoenzymes | 1 | 2010 | 285 | 0.080 |
Why?
| | Arginine | 1 | 2010 | 236 | 0.080 |
Why?
| | Chromosomes, Human | 1 | 2009 | 39 | 0.080 |
Why?
| | Graft Rejection | 1 | 2012 | 516 | 0.080 |
Why?
| | Caribbean Region | 4 | 2011 | 19 | 0.080 |
Why?
| | Receptors, Leptin | 1 | 2009 | 24 | 0.080 |
Why?
| | Confidence Intervals | 2 | 2014 | 309 | 0.080 |
Why?
| | Interferon-alpha | 1 | 2010 | 187 | 0.080 |
Why?
| | Nephrotic Syndrome | 1 | 1989 | 24 | 0.080 |
Why?
| | Agammaglobulinemia | 1 | 1989 | 30 | 0.080 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 52 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2022 | 350 | 0.080 |
Why?
| | Cholesterol | 2 | 2015 | 368 | 0.080 |
Why?
| | Genotyping Techniques | 2 | 2019 | 69 | 0.080 |
Why?
| | Alcoholism | 3 | 2005 | 714 | 0.080 |
Why?
| | Thromboxane B2 | 3 | 2018 | 26 | 0.080 |
Why?
| | Proteoglycans | 1 | 2009 | 107 | 0.080 |
Why?
| | Cognition | 1 | 2015 | 989 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 647 | 0.080 |
Why?
| | Research Design | 2 | 2019 | 931 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 994 | 0.070 |
Why?
| | Siblings | 2 | 2011 | 222 | 0.070 |
Why?
| | Databases, Factual | 1 | 2012 | 1128 | 0.070 |
Why?
| | Infant, Newborn | 6 | 2012 | 5035 | 0.070 |
Why?
| | Chromosomes, Human, Pair 17 | 3 | 2019 | 56 | 0.070 |
Why?
| | Antigens, CD | 1 | 2010 | 443 | 0.070 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2007 | 19 | 0.070 |
Why?
| | Registries | 1 | 2014 | 1759 | 0.070 |
Why?
| | Age of Onset | 3 | 2013 | 448 | 0.070 |
Why?
| | Prospective Studies | 5 | 2020 | 6217 | 0.070 |
Why?
| | Thrombophilia | 1 | 2007 | 66 | 0.070 |
Why?
| | Inheritance Patterns | 1 | 2006 | 45 | 0.070 |
Why?
| | Deoxyribonuclease HindIII | 1 | 2006 | 2 | 0.070 |
Why?
| | Europe | 2 | 2020 | 336 | 0.070 |
Why?
| | alpha-Linolenic Acid | 2 | 2017 | 7 | 0.070 |
Why?
| | Meta-Analysis as Topic | 3 | 2012 | 161 | 0.070 |
Why?
| | Neoplasm Proteins | 2 | 2022 | 385 | 0.070 |
Why?
| | Adenosine Diphosphate | 2 | 2017 | 81 | 0.070 |
Why?
| | Platelet Count | 2 | 2016 | 81 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 2 | 2019 | 27 | 0.060 |
Why?
| | Glucose | 2 | 2022 | 897 | 0.060 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 372 | 0.060 |
Why?
| | Transfection | 3 | 2016 | 870 | 0.060 |
Why?
| | Epinephrine | 2 | 2017 | 164 | 0.060 |
Why?
| | Mucins | 1 | 2005 | 61 | 0.060 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1728 | 0.060 |
Why?
| | Disease Models, Animal | 1 | 2014 | 3542 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2005 | 143 | 0.060 |
Why?
| | Complement C3 | 1 | 2006 | 189 | 0.060 |
Why?
| | Receptors, Prostaglandin | 1 | 2004 | 22 | 0.060 |
Why?
| | Mites | 1 | 2004 | 3 | 0.060 |
Why?
| | Societies, Medical | 2 | 2019 | 663 | 0.060 |
Why?
| | Eye Proteins | 2 | 2021 | 71 | 0.060 |
Why?
| | Sex Factors | 3 | 2014 | 1717 | 0.060 |
Why?
| | Gene Targeting | 2 | 2020 | 75 | 0.060 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 149 | 0.060 |
Why?
| | Matched-Pair Analysis | 1 | 2003 | 33 | 0.060 |
Why?
| | Chromosomes, Human, Pair 14 | 2 | 2014 | 16 | 0.060 |
Why?
| | Adult Children | 1 | 2003 | 21 | 0.060 |
Why?
| | Electroencephalography | 1 | 2005 | 362 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1521 | 0.060 |
Why?
| | Time | 1 | 2003 | 70 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2004 | 111 | 0.060 |
Why?
| | Guanine Nucleotide Dissociation Inhibitors | 1 | 2023 | 2 | 0.050 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 429 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2016 | 2557 | 0.050 |
Why?
| | Genes | 1 | 2003 | 224 | 0.050 |
Why?
| | Cooperative Behavior | 1 | 2005 | 381 | 0.050 |
Why?
| | Point Mutation | 1 | 2004 | 216 | 0.050 |
Why?
| | Aminopeptidases | 1 | 2023 | 9 | 0.050 |
Why?
| | Environment | 2 | 2010 | 336 | 0.050 |
Why?
| | Cell Line | 3 | 2015 | 2639 | 0.050 |
Why?
| | Genes, Reporter | 2 | 2015 | 257 | 0.050 |
Why?
| | Pruritus | 1 | 2023 | 60 | 0.050 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2022 | 15 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 105 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 334 | 0.050 |
Why?
| | Fruit | 1 | 2023 | 128 | 0.050 |
Why?
| | Colorado | 2 | 2024 | 4086 | 0.050 |
Why?
| | Vegetables | 1 | 2023 | 133 | 0.050 |
Why?
| | Age Factors | 3 | 2003 | 2890 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2023 | 224 | 0.050 |
Why?
| | Gene Expression | 3 | 2015 | 1420 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 3334 | 0.050 |
Why?
| | Internationality | 2 | 2013 | 144 | 0.050 |
Why?
| | RGS Proteins | 1 | 2021 | 12 | 0.050 |
Why?
| | Blood Proteins | 1 | 2023 | 232 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2022 | 93 | 0.050 |
Why?
| | Postmenopause | 1 | 2023 | 303 | 0.050 |
Why?
| | Sepsis | 1 | 2007 | 508 | 0.050 |
Why?
| | K562 Cells | 1 | 2021 | 73 | 0.050 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 17 | 0.050 |
Why?
| | INDEL Mutation | 1 | 2021 | 12 | 0.050 |
Why?
| | Colombia | 2 | 2013 | 34 | 0.050 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2021 | 24 | 0.050 |
Why?
| | Receptors, LDL | 1 | 2020 | 38 | 0.050 |
Why?
| | alpha Karyopherins | 1 | 2020 | 13 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2000 | 13 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2021 | 98 | 0.050 |
Why?
| | Lymphocytosis | 1 | 2000 | 9 | 0.050 |
Why?
| | Tripartite Motif Proteins | 1 | 2020 | 30 | 0.050 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 80 | 0.050 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 139 | 0.050 |
Why?
| | Sample Size | 1 | 2021 | 114 | 0.050 |
Why?
| | Gene Editing | 1 | 2021 | 57 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2021 | 61 | 0.040 |
Why?
| | Dioxygenases | 1 | 2020 | 25 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2006 | 723 | 0.040 |
Why?
| | Lod Score | 3 | 2009 | 65 | 0.040 |
Why?
| | Eating | 1 | 2023 | 345 | 0.040 |
Why?
| | Population Density | 1 | 2021 | 94 | 0.040 |
Why?
| | Lens, Crystalline | 1 | 2001 | 96 | 0.040 |
Why?
| | Mucin-5B | 1 | 2022 | 183 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2020 | 49 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 524 | 0.040 |
Why?
| | Machine Learning | 1 | 2024 | 318 | 0.040 |
Why?
| | Names | 1 | 2000 | 12 | 0.040 |
Why?
| | Mutagenesis | 1 | 2021 | 170 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 172 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2020 | 24 | 0.040 |
Why?
| | Emigration and Immigration | 1 | 2000 | 44 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 51 | 0.040 |
Why?
| | North America | 2 | 2011 | 257 | 0.040 |
Why?
| | Body Weight | 1 | 2003 | 869 | 0.040 |
Why?
| | Prevalence | 2 | 2016 | 2249 | 0.040 |
Why?
| | Information Dissemination | 1 | 2021 | 187 | 0.040 |
Why?
| | Siberia | 1 | 2019 | 9 | 0.040 |
Why?
| | Fibrinolysis | 1 | 2021 | 158 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 1080 | 0.040 |
Why?
| | Recombinases | 1 | 2019 | 6 | 0.040 |
Why?
| | Flame Ionization | 1 | 2019 | 2 | 0.040 |
Why?
| | Cataract | 1 | 2001 | 185 | 0.040 |
Why?
| | Linear Models | 2 | 2017 | 770 | 0.040 |
Why?
| | Event-Related Potentials, P300 | 1 | 1999 | 12 | 0.040 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2019 | 33 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2018 | 30 | 0.040 |
Why?
| | Cloud Computing | 1 | 2019 | 7 | 0.040 |
Why?
| | Monoamine Oxidase | 1 | 1999 | 27 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 552 | 0.040 |
Why?
| | Limit of Detection | 1 | 2019 | 53 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 125 | 0.040 |
Why?
| | RNA Splicing Factors | 1 | 2019 | 49 | 0.040 |
Why?
| | Neoplasms | 1 | 2012 | 2105 | 0.040 |
Why?
| | Organ Size | 1 | 2019 | 435 | 0.040 |
Why?
| | Skin | 1 | 2023 | 659 | 0.040 |
Why?
| | Reference Standards | 1 | 2019 | 159 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2018 | 9 | 0.040 |
Why?
| | Disease Susceptibility | 2 | 2014 | 316 | 0.040 |
Why?
| | Virus Diseases | 1 | 2000 | 195 | 0.040 |
Why?
| | Proteome | 1 | 2021 | 339 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 386 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2019 | 642 | 0.040 |
Why?
| | Histone Code | 1 | 2017 | 28 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 843 | 0.040 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2017 | 32 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1745 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1370 | 0.040 |
Why?
| | Time Factors | 2 | 2019 | 6124 | 0.040 |
Why?
| | Alternative Splicing | 1 | 2019 | 188 | 0.040 |
Why?
| | Eosinophils | 1 | 2019 | 278 | 0.040 |
Why?
| | Adipocytes | 1 | 2018 | 188 | 0.040 |
Why?
| | Selection, Genetic | 1 | 2019 | 243 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4420 | 0.040 |
Why?
| | Workflow | 1 | 2018 | 135 | 0.040 |
Why?
| | Program Evaluation | 1 | 2021 | 822 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2000 | 521 | 0.040 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 8 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2017 | 54 | 0.040 |
Why?
| | Apolipoprotein E2 | 1 | 2016 | 3 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2020 | 610 | 0.030 |
Why?
| | Data Accuracy | 1 | 2017 | 48 | 0.030 |
Why?
| | Interleukin-33 | 1 | 2017 | 38 | 0.030 |
Why?
| | Demography | 1 | 2017 | 262 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 460 | 0.030 |
Why?
| | Denmark | 1 | 2016 | 39 | 0.030 |
Why?
| | Massachusetts | 1 | 2017 | 134 | 0.030 |
Why?
| | Mean Platelet Volume | 1 | 2016 | 3 | 0.030 |
Why?
| | Allelic Imbalance | 1 | 2016 | 7 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2014 | 965 | 0.030 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 65 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 28 | 0.030 |
Why?
| | China | 1 | 2017 | 162 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2016 | 52 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 75 | 0.030 |
Why?
| | Hematocrit | 1 | 2016 | 85 | 0.030 |
Why?
| | DNA | 1 | 2023 | 1351 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1184 | 0.030 |
Why?
| | Stearic Acids | 1 | 2015 | 12 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2020 | 1662 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2016 | 97 | 0.030 |
Why?
| | Sarcoglycans | 1 | 2015 | 4 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 262 | 0.030 |
Why?
| | Social Class | 1 | 2017 | 204 | 0.030 |
Why?
| | Bias | 1 | 2016 | 180 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 396 | 0.030 |
Why?
| | Lung Volume Measurements | 1 | 2015 | 45 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1435 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2015 | 65 | 0.030 |
Why?
| | Nutritional Status | 1 | 2017 | 286 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 31 | 0.030 |
Why?
| | Vascular Calcification | 1 | 2016 | 107 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2017 | 299 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 316 | 0.030 |
Why?
| | Potassium Channels | 1 | 2015 | 121 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 453 | 0.030 |
Why?
| | Pneumothorax | 1 | 2014 | 40 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2014 | 48 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 1846 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2022 | 944 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 799 | 0.030 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 71 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2015 | 95 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 304 | 0.030 |
Why?
| | Regression Analysis | 2 | 2007 | 946 | 0.030 |
Why?
| | Hemoglobins | 1 | 2016 | 314 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2018 | 374 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2015 | 177 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 334 | 0.030 |
Why?
| | Diet, Western | 1 | 2014 | 66 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2019 | 2209 | 0.030 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 100 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 4625 | 0.030 |
Why?
| | Jamaica | 1 | 2013 | 1 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 812 | 0.030 |
Why?
| | District of Columbia | 1 | 2013 | 24 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 168 | 0.030 |
Why?
| | Educational Status | 1 | 2015 | 412 | 0.030 |
Why?
| | Cotinine | 1 | 2013 | 69 | 0.030 |
Why?
| | Gene Order | 1 | 2012 | 24 | 0.030 |
Why?
| | New York | 1 | 2013 | 106 | 0.030 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2012 | 18 | 0.030 |
Why?
| | Dynactin Complex | 1 | 2012 | 4 | 0.030 |
Why?
| | Immunity, Mucosal | 1 | 2013 | 84 | 0.030 |
Why?
| | Untranslated Regions | 1 | 2012 | 3 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 815 | 0.020 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 386 | 0.020 |
Why?
| | Wales | 1 | 2011 | 17 | 0.020 |
Why?
| | Overweight | 1 | 2015 | 471 | 0.020 |
Why?
| | Adolescent Development | 1 | 2012 | 83 | 0.020 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 322 | 0.020 |
Why?
| | Canada | 1 | 2012 | 322 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 37 | 0.020 |
Why?
| | Microsatellite Repeats | 2 | 2003 | 136 | 0.020 |
Why?
| | England | 1 | 2011 | 65 | 0.020 |
Why?
| | Biological Evolution | 1 | 2015 | 416 | 0.020 |
Why?
| | Eicosapentaenoic Acid | 1 | 2011 | 28 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2011 | 72 | 0.020 |
Why?
| | X Chromosome Inactivation | 1 | 2011 | 21 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2014 | 476 | 0.020 |
Why?
| | Luciferases | 1 | 2011 | 142 | 0.020 |
Why?
| | Costa Rica | 1 | 2010 | 16 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1590 | 0.020 |
Why?
| | Artifacts | 1 | 2011 | 113 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2015 | 696 | 0.020 |
Why?
| | Codon, Nonsense | 1 | 2010 | 37 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 339 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 335 | 0.020 |
Why?
| | Introns | 1 | 2011 | 227 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 41 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 127 | 0.020 |
Why?
| | Urban Population | 1 | 2012 | 398 | 0.020 |
Why?
| | Markov Chains | 1 | 2010 | 114 | 0.020 |
Why?
| | Albuterol | 1 | 2010 | 102 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 265 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 205 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2010 | 201 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2009 | 2582 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 912 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 345 | 0.020 |
Why?
| | Waist Circumference | 1 | 2010 | 122 | 0.020 |
Why?
| | Kainic Acid | 1 | 2009 | 31 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1226 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2009 | 37 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2009 | 139 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 2358 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2010 | 240 | 0.020 |
Why?
| | Disease | 1 | 2009 | 85 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 225 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1691 | 0.020 |
Why?
| | Korea | 1 | 2007 | 8 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 2973 | 0.020 |
Why?
| | beta-Thromboglobulin | 1 | 2007 | 3 | 0.020 |
Why?
| | Binding Sites | 1 | 2010 | 1176 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2010 | 436 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1528 | 0.020 |
Why?
| | Drug Resistance | 1 | 2007 | 158 | 0.020 |
Why?
| | Genetic Testing | 2 | 1999 | 379 | 0.020 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 29 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 516 | 0.020 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 31 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2005 | 108 | 0.020 |
Why?
| | Hepatitis A Antibodies | 1 | 2005 | 3 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2005 | 35 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2005 | 26 | 0.020 |
Why?
| | Hepatitis A | 1 | 2005 | 26 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2018 | 9089 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2005 | 75 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2005 | 138 | 0.020 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2004 | 25 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2009 | 1635 | 0.010 |
Why?
| | Antigens, Dermatophagoides | 1 | 2004 | 10 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 22 | 0.010 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2004 | 13 | 0.010 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 137 | 0.010 |
Why?
| | Gene Deletion | 1 | 2006 | 356 | 0.010 |
Why?
| | Germany | 1 | 2004 | 84 | 0.010 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2004 | 28 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2004 | 129 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 292 | 0.010 |
Why?
| | Aquaporins | 1 | 2001 | 8 | 0.010 |
Why?
| | Osmosis | 1 | 2001 | 15 | 0.010 |
Why?
| | Chimera | 1 | 2001 | 59 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2001 | 140 | 0.010 |
Why?
| | Optics and Photonics | 1 | 2001 | 41 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 148 | 0.010 |
Why?
| | Lasers | 1 | 2001 | 121 | 0.010 |
Why?
| | Western Australia | 1 | 2001 | 6 | 0.010 |
Why?
| | HIV-2 | 1 | 2000 | 15 | 0.010 |
Why?
| | Cost Control | 1 | 2000 | 38 | 0.010 |
Why?
| | Herpesvirus 6, Human | 1 | 2000 | 13 | 0.010 |
Why?
| | Toxoplasma | 1 | 2000 | 30 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 125 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2000 | 144 | 0.010 |
Why?
| | Expert Testimony | 1 | 1999 | 36 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2791 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 2000 | 250 | 0.010 |
Why?
| | Observer Variation | 1 | 1999 | 295 | 0.010 |
Why?
| | Lymphocytes | 1 | 2000 | 332 | 0.010 |
Why?
| | Water | 1 | 2001 | 399 | 0.010 |
Why?
| | Eosinophilia | 1 | 1999 | 186 | 0.010 |
Why?
| | HIV-1 | 1 | 2000 | 768 | 0.010 |
Why?
| | Physicians | 1 | 1999 | 772 | 0.010 |
Why?
|
|
Mathias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|